Avenciguat
- Generic Name
- Avenciguat
Robust Pipeline of 80+ Therapies Advancing for Chronic Kidney Disease Treatment in 2025
• DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern.
• Key late-stage candidates include AstraZeneca's Baxdrostat and Novo Nordisk's Ziltivekimab, targeting different pathways in CKD progression with promising clinical results.
• Multiple novel mechanisms are being explored across all development stages, including aldosterone synthase inhibition, anti-inflammatory approaches, and soluble guanylate cyclase activation, expanding potential treatment options.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath